Checkpoint inhibitors in patients with advanced, refractory biliary tract cancers

被引：0
|
作者：
Liddell, S. [1 ]
Wintheiser, G. [1 ]
Jin, Z. [1 ]
Tran, N. [1 ]
Mahipal, A. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-278
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [31] Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
    Kang, Sandra
    El-Rayes, Bassel F.
    Akce, Mehmet
    CANCERS, 2022, 14 (07)
  • [32] Treatment of advanced urogenital cancers with immune checkpoint inhibitors
    Jung, Eun Hee
    Kim, Se Hyun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 349 - 357
  • [33] Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
    Kim, Hongsik
    Kim, Ryul
    Jo, Hyunji
    Kim, Hye Ryeon
    Hong, Joohyun
    Ha, Sang Yun
    Park, Joon Oh
    Kim, Seung Tae
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [34] Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Jonathan D Mizrahi
    Valerie Gunchick
    Kabir Mody
    Lianchun Xiao
    Phanikeerthi Surapaneni
    Rachna T Shroff
    Vaibhav Sahai
    World Journal of Gastrointestinal Oncology, 2020, (01) : 83 - 91
  • [35] FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Frega, Giorgio
    Di Federico, Alessandro
    Brandi, Giovanni
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (05) : 567 - 574
  • [36] A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers
    Den Linger, Crystal S.
    Meropol, Neal J.
    Li, Tianyu
    Lewis, Nancy L.
    Engstrom, Paul F.
    Weiner, Louis M.
    Cheng, Jonathan D.
    Alpaugh, R. Katherine
    Cooper, Harry
    Wright, John J.
    Cohen, Steven J.
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 81 - 86
  • [37] Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
    Mizrahi, Jonathan D.
    Gunchick, Valerie
    Mody, Kabir
    Xiao, Lianchun
    Surapaneni, Phanikeerthi
    Shroff, Rachna T.
    Sahai, Vaibhav
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (01) : 83 - 91
  • [38] Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma
    Chakrabarti, Sakti
    Zemla, Tyler J.
    Ahn, Daniel H.
    Ou, Fang-Shu
    Fruth, Briant
    Borad, Mitesh J.
    Hartgers, Mindy L.
    Wessling, Jaclynn
    Walkes, Rachel L.
    Alberts, Steven R.
    McWilliams, Robert R.
    Liu, Minetta C.
    Durgin, Lori M.
    Bekaii-Saab, Tanios S.
    Mahipal, Amit
    ONCOLOGIST, 2020, 25 (05): : 380 - +
  • [39] Second-line therapies in advanced biliary tract cancers
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Borad, Mitesh J.
    Mahipal, Amit
    LANCET ONCOLOGY, 2020, 21 (01): : E29 - E41
  • [40] Systemic chemotherapy for advanced biliary tract cancers: present and future
    Malka, D.
    Boige, V.
    Ducreux, M.
    ONCOLOGIE, 2010, 12 (10) : 623 - 628
12345